溴隐亭治疗围产期心肌病:多中心随机研究
这项多中心随机试验将63例左心室射血分数(LVEF)≤35%的围产期心肌病(PPCM)患者随机分为短期(1周)或长期(8周)溴隐亭治疗组,均联合标准心衰治疗。主要终点为基线至6个月心脏磁共振评估的LVEF变化。两组LVEF均显著改善,短期组ΔLVEF为+21±11%,长期组为+24±11%(P=0.381),完全恢复率分别为52%和68%,无显著差异;溴隐亭耐受良好,无死亡、心脏移植或左室辅助装置植入。
要点
- 溴隐亭联合标准心衰治疗可使PPCM患者LVEF从约28%恢复至约50%。
- 1周与8周溴隐亭疗程的LVEF改善无显著差异(P=0.381)。
- 8周组完全恢复率68% vs 1周组52%,但差异无统计学意义。
核心结论
- 溴隐亭治疗与PPCM患者高完全恢复率和低发病率、低死亡率相关,优于未使用溴隐亭的其他PPCM队列。
- 1周与8周溴隐亭治疗无显著差异,提示标准心衰治疗加用1周溴隐亭已有益,8周组完全恢复有更好趋势。
研究设计与样本
- 多中心随机试验,纳入63例LVEF≤35%的PPCM患者,随机接受短期(1周:溴隐亭2.5 mg,7天)或长期(8周:5 mg用2周后2.5 mg用6周)溴隐亭治疗,均联合标准心衰治疗。
- 主要终点为基线至6个月心脏磁共振评估的LVEF变化(ΔLVEF)。
主要发现
- 1周组LVEF从28±10%升至49±12%,ΔLVEF为+21±11%;8周组从27±10%升至51±10%,ΔLVEF为+24±11%(ΔLVEF组间P=0.381)。
- 完全恢复(LVEF≥50%)在1周组为52%,8周组为68%。
- 心衰住院率1周组9.7% vs 8周组6.5%(P=0.651)。
- 8周组6个月后未完全恢复的风险有更低趋势。
- 研究期间无患者需要心脏移植、左室辅助装置或死亡。
临床怎么用
- 对于LVEF≤35%的PPCM患者,可在标准心衰治疗基础上加用溴隐亭,1周短期疗程已显示获益。
- 8周疗程可能有利于提高完全恢复率,但需权衡疗程与获益,当前证据未显示显著差异。
局限性
- 样本量较小(63例),可能不足以检测组间差异。
- 原文未报告盲法、随访时长细节及统计效能等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM. METHODS AND RESULTS: In this multicentre trial, 63 PPCM patients with left ventricular ejection fraction (LVEF) ≤35% were randomly assigned to short-term (1W: bromocriptine, 2.5 mg, 7 days) or long-term bromocriptine treatment (8W: 5 mg for 2 weeks followed by 2.5 mg for 6 weeks) in addition to standard heart failure therapy. Primary end point was LVEF change (delta) from baseline to 6 months assessed by magnetic resonance imaging. Bromocriptine was well tolerated. Left ventricular ejection fraction increased from 28 ± 10% to 49 ± 12% with a delta-LVEF of + 21 ± 11% in the 1W-group, and from 27 ± 10% to 51 ± 10% with a delta-LVEF of + 24 ± 11% in the 8W-group (delta-LVEF: P = 0.381). Full-recovery (LVEF ≥ 50%) was present in 52% of the 1W- and in 68% of the 8W-group with no differences in secondary end points between both groups (hospitalizations for heart failure: 1W: 9.7% vs. 8W: 6.5%, P = 0.651). The risk within the 8W-group to fail full-recovery after 6 months tended to be lower. No patient in the study needed heart transplantation, LV assist device or died. CONCLUSION: Bromocriptine treatment was associated with high rate of full LV-recovery and low morbidity and mortality in PPCM patients compared with other PPCM cohorts not treated with bromocriptine. No significant differences were observed between 1W and 8W treatment suggesting that 1-week addition of bromocriptine to standard heart failure treatment is already beneficial with a trend for better full-recovery in the 8W group. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, study number: NCT00998556.
引用
- Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017. PMID: 28934837. doi:10.1093/eurheartj/ehx355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。